Skip to main content
Equibles
CALC logo

CALC · CalciMedica, Inc.

Track CALC — free

Use CALC with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.17 -0.03 (-1.36%) At close · Sep 4
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the Company's current operating plans, management believes its cash and cash equivalents may not be sufficient to fund its operations for a period of one year following the issuance of these financial statements. As a result, there is substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 11, 2026
Market Cap
$14.34M
Shares
6.83M

CALC metrics

37 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.17
Market cap
$14.34M

Price action

19 metrics
Price change (1W)
—
Price change (30D)
+1.4%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Beta
—
RSI (14D)
—
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
6.83M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.6
reciprocal yield 38.4%
FCF yield
-133.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-148.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-07

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$19.63M
Net income (TTM)
−$21.24M
Trailing 12 months
Diluted EPS (TTM)
$-6.80
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.09

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+14.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-385.3%
Return on assets
-108.9%
Debt / equity
—
Current ratio
5.6
EBITDA (TTM)
—
Free cash flow (TTM)
−$19.12M
Quick ratio
5.6
Interest coverage
-15.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$18.62M
Latest balance sheet
Cash & equivalents
$18.62M
Total assets
$19.50M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$19.11M
Capital expenditures (TTM)
$14,000
R&D (TTM)
$12.54M
SG&A (TTM)
—
Stock compensation (TTM)
$2.35M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
32
13F filer change QoQ
+4
Institutional ownership
24.6%

Short interest

3 metrics
Short interest
0.9%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
45 / 100

Insider activity

2 metrics
Net insider buying (90D)
$199,999
Insider-sentiment score
86 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1534133 CUSIP 38942Q202 13F (30d) 30 filings 30 filers Visit website Investor relations